IDRA-21 POWDER (1 GRAM)

$18.99

IDRA-21 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

×

Also Available In:
Liquid Option >>

SKU: ULNIDR21POW1 Categories: , Tags: , , , ,

Description

IDRA-21 Nootropic Powder

 

 

 

CAS Number 22503-72-6
Other Names IDRA 21, 22503-72-6, 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide, 689UW7PT68, (+)-IDRA-21, (-)-IDRA-21, Biomol-NT_000225, D0S0VZ
IUPAC Name 7-chloro-3-methyl-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine 1,1-dioxide
Molecular Formula C₈H₉ClN₂O₂S
Molecular Weight 232.69
Purity ≥99% Pure (LC-MS)
Liquid Availability 30mL liquid (10mg/mL, 300mg bottle)
Powder Availability  1 gram
Gel Availability N/A
Storage Store in cool dry environment, away from direct sunlight.
Terms All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

IDRA-21 is a nootropic compound derived from the chemical structure of benzothiadiazine. Due to its mechanism of action, IDRA-21 is categorized as a member of the ampakine family as the compound primarily works as a positive allosteric modulator of ionotropic glutamate AMPA receptors. AMPA receptors tend to immediately regulate glutamate levels following activation and are widely known for their ability to promote synaptic transmission and plasticity. That being said, IDRA-21 has shown potential in improving cognition and learning while reducing cognitive degeneration typically associated with aging.

As a member of the ampakine family, IDRA-21 is closely related to the compound Aniracetam. Aniracetam is a nootropic that has shown promise in supporting memory formation and retention, mood, and focus. Various animal-based studies have examined how IDRA-21 is capable of reversing cognitive deficits in comparison to Aniracetam. These studies begin by inducing cognitive decline through administration of alprazolam or scopolamine. Subjects, typically rodents, are then treated with either Aniracetam or IDRA-21. Results found that IDRA-21 is not only 10-30 times more potent than Aniracetam, but also stays active for approximately 48 hours.

Effects of IDRA-21 on Memory and Performance

Additional benefits of IDRA-21 are associated with the work of the AMPA receptors that regulate glutamate levels. Cognition and learning tends to be improved through the increase of glutamate levels, leading to the promotion of long term potentiation and synaptic connections throughout the brain. A notable study tested how laboratory rats performed in a water maze following administration of IDRA-21. Results found that the rats receiving IDRA-21 performed far better by exiting the maze faster than those receiving a placebo drug (https://www.linkedin.com/pulse/idra-21-powder-dosage-half-life-benefits-side-effects-wise-powder/).

Another important study conducted by Buccafusco et. Al examined how administering IDRA-21 to both young and old rhesus monkeys affected performance levels. Results of the study were measured by observing the monkeys’ performance of a delayed matching-to-sample (DMTS) test. Doses of IDRA-21 varying from 0.15-10 mg/kg were administered to the test subjects who were then tested at different points of time over a 48 hour testing period. In young monkeys, the most improvement seen in the experimental group was a 34% increase in performance compared to the placebo group. Additional fixed doses given were separated by 3 days in order to see if the compound had a cumulative effect on the monkeys. Researchers observed that over the course of 3 weeks, performance levels gradually increased in the monkeys receiving intermittent doses of the compound.

Aged monkeys, 20-years-old and up, were then given doses of IDRA-21 within the same range as the young monkeys and expected to perform the DMTS test. Results found that over the same dosage range the aged monkeys experienced an increase in overall performance levels, however, the improvement was not as drastic as in the young monkeys. The young monkeys performed at 34% better than those given a vehicle while the aged monkeys performed approximately 18% better than the vehicle. Additionally, the researchers observed that the older monkeys were far more sensitive to variations in the dosage while also exhibiting shorter task latency.

Despite the differences between the old and young experimental groups of monkeys, the data emphasizes the overall improvement seen in both groups without any notable side effects following administration. The improvement in performance in the older monkeys is especially important as it indicates that AMPA receptor modulators such as IDRA-21 can effectively and efficiently assist in combating cognitive decline (https://pubmed.ncbi.nlm.nih.gov/14654093/).

A similar study was conducted specifically in young monkeys that were tasked with completing the same DMTS test as well as a visual recognition test with 4 added delays of 10s, 30s, 60s, and 90s. However, this experiment compared IDRA-21 to a similar cognitive enhancement agent, huperzine A. Huperzine A is known to increase levels of acetylcholine (ACh) in the brain since it acts as an inhibitor of acetylcholinesterase (AChE).

After gathering data on the monkeys’ performance on the two tests, the researchers found huperzine A did not improve performance levels on either task. However, what was interesting about this compound was that it had a negative correlation with the baseline performance levels, so if the monkeys performed poorly at baseline, the drug decreased performance, but if they performed well at baseline there was no additional improvement. On the other hand, the monkeys that were administered IDRA-21 experienced a drastic improvement in performance during the visual recognition task, specifically with the 90s delay. The results of this study solidify the claim that IDRA-21 can work as an effective treatment for cognitive and memory deficiencies (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073152/).

The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.

IDRA-21 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

Pure IDRA 21 For Sale Pure IDRA 21 For Sale Pure IDRA 21 For Sale

 

Pure IDRA-21 Nootropic For Sale Certificate of Authenticity COA

File Name View/Download
10-21-2020-IDRA-21-Certificate-of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)

 

Additional information

Options

,